These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8692758)

  • 1. [Bone and bone marrow metastases of prostatic adenocarcinoma: the serum level of prostate-specific antigen may be normal].
    Marlier S; Durupt S; de Jaureguiberry JP; Marlier-Civatte M; Peybere B; Jaubert D
    Presse Med; 1996 May 4-11; 25(16):777. PubMed ID: 8692758
    [No Abstract]   [Full Text] [Related]  

  • 2. High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer.
    Furuya Y; Cho S; Ohta S; Sato N; Kotake T; Masai M
    J Urol; 2001 Jul; 166(1):213. PubMed ID: 11435864
    [No Abstract]   [Full Text] [Related]  

  • 3. Bone metastases from prostate cancer without elevated prostate-specific antigen levels: diagnosis by anti-PSA immunostaining.
    Berthelot JM; Gouin F; Denis M; Nomballais MF; Maugars Y; Blaive-Cervi S; Prost A
    Rev Rhum Engl Ed; 1995 Jan; 62(1):54-5. PubMed ID: 7540487
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlation between bone metabolic markers and bone scan in prostatic cancer.
    Maeda H; Koizumi M; Yoshimura K; Yamauchi T; Kawai T; Ogata E
    J Urol; 1997 Feb; 157(2):539-43. PubMed ID: 8996351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metastatic prostate cancer associated with low levels of prostate-specific antigen].
    Diaz S; Salirrosas M
    Rev Peru Med Exp Salud Publica; 2012; 29(4):541-4. PubMed ID: 23338642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer.
    Kanoh Y; Ohtani N; Mashiko T; Ohtani S; Nishikawa T; Egawa S; Baba S; Ohtani H
    Anticancer Res; 2001; 21(1B):551-6. PubMed ID: 11299802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Morphological and histomorphometric study of bone and bone marrow metastases of prostatic adenocarcinoma].
    Cambon C; Pinel B; Le Loët X; Tayot J; Basuyau JP; Deshayes P
    Rev Rhum Mal Osteoartic; 1984 Dec; 51(11):643-50. PubMed ID: 6523015
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostatic carcinoma presenting with painless parotid mass.
    Kirkali Z; Koyuncuoğlu M; Pabuçcuoğlu U; Güneri A; Mungan U
    Urology; 1995 Sep; 46(3):406-7. PubMed ID: 7544935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Usefulness of bone-specific alkaline phosphatase for bone metastases detection in prostate cancer].
    Rasch-Isla Muñoz A; Cataño Cataño JG
    Arch Esp Urol; 2004 Sep; 57(7):693-8. PubMed ID: 15536950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
    Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H
    Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic osteomalacia.
    Rapoport J
    Isr Med Assoc J; 2000 Dec; 2(12):942-3. PubMed ID: 11344782
    [No Abstract]   [Full Text] [Related]  

  • 14. Recurrence of prostate adenocarcinoma presenting with multiple myeloma simulating skeletal metastases of prostate adenocarcinoma.
    Huang E; Teh BS; Saleem A; Butler EB
    Urology; 2002 Dec; 60(6):1111. PubMed ID: 12475684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostatic meningeal carcinomatosis with low serum level of prostate-specific antigen.
    Honda M; Miyagawa I
    Urology; 2005 Dec; 66(6):1320. PubMed ID: 16360475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen level and risk of bone metastasis in Sudanese patients with prostate cancer.
    Khalid KE; Brair AI; Elhaj AM; Ali KE
    Saudi J Kidney Dis Transpl; 2011 Sep; 22(5):1041-3. PubMed ID: 21912047
    [No Abstract]   [Full Text] [Related]  

  • 18. [Correlation between specific prostatic antigen and findings with total body bone scintigraphy].
    López M; Montes De Oca L; Bernardo N; Scorticati C; Suárez P; Bencardino F; De Lasa T; Sotero Falco E; Coimbra F; Scorticati C
    Arch Esp Urol; 1996 Nov; 49(9):953-5. PubMed ID: 9133295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.
    Mystakidou K; Katsouda E; Parpa E; Vlahos L
    J Pain Palliat Care Pharmacother; 2005; 19(3):41-5. PubMed ID: 16219610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chest-Wall Metastasis of Prostate Cancer.
    Matei V; Bhushan S
    J Gen Intern Med; 2015 Dec; 30(12):1888. PubMed ID: 25759188
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.